William Blair analyst Myles Minter reiterated a Buy rating on Minerva Neurosciences (NERV – Research Report) on February 5. The company’s shares closed last Monday at $8.48, close to its 52-week high of $9.23.
According to TipRanks.com, Minter is a 5-star analyst with an average return of 136.9% and a 100.0% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Axsome Therapeutics, and Karuna Therapeutics.
Minerva Neurosciences has an analyst consensus of Strong Buy, with a price target consensus of $19.00.
www.analystratings.com/articles/...rating-from-william-blair/
www.minervaneurosciences.com/